Trial Profile

Pre-Approval Access for Efgartigimod PH20 SC in Patients With Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Status: Recruiting

Phase of Trial: Clinical Phase Unknown

Latest Information Update: 31 Mar 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Efgartigimod alfa (Primary) ; Efgartigimod alfa (Primary)
Indications Myasthenia gravis
Focus Expanded access; Therapeutic Use
Sponsors argenx

Most Recent Events

24 Mar 2026 Status changed to recruiting.
26 Apr 2022 Results (As of September 24, 2021,n= 10 )presented at the 74th Annual Meeting of the American Academy of Neurology 2022
25 Apr 2022 Status changed from recruiting to completed.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com